160 related articles for article (PubMed ID: 31361655)
1. Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study.
Sheppard J; Kannarr S; Luchs J; Malhotra R; Justice A; Ogundele A; Darby C; Bacharach J
Eye Contact Lens; 2020 Jan; 46 Suppl 1():S14-S19. PubMed ID: 31361655
[TBL] [Abstract][Full Text] [Related]
2. The Effect of OTX-101 on Tear Production in Patients with Severe Tear-deficient Dry Eye Disease: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.
Toyos M; Gupta PK; Mitchell B; Karpecki P
Curr Eye Res; 2022 Feb; 47(2):220-224. PubMed ID: 34459350
[TBL] [Abstract][Full Text] [Related]
3. Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.
Malhotra R; Devries DK; Luchs J; Kabat A; Schechter BA; Shen Lee B; Shettle L; Smyth-Medina R; Ogundele A; Darby C; Bacharach J; Karpecki P
Cornea; 2019 Oct; 38(10):1259-1265. PubMed ID: 31306284
[TBL] [Abstract][Full Text] [Related]
4. Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials.
Smyth-Medina R; Johnston J; Devries DK; Jasper A; Kannarr SR; Schechter BA; Shen Lee B; Varghese G; Ogundele A; Darby CH; Karpecki P; Luchs J
J Ocul Pharmacol Ther; 2019 Sep; 35(7):388-394. PubMed ID: 31373837
[No Abstract] [Full Text] [Related]
5. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
[TBL] [Abstract][Full Text] [Related]
6. Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca.
Sheppard J; Bergmann M; Schechter BA; Luchs J; Ogundele A; Karpecki P
Clin Ophthalmol; 2021; 15():129-140. PubMed ID: 33469259
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial.
Rao AT; Gupta A; Chauhan T; Basu S; Batra N; Sharma N; Sangwan VS; Gupta V; Mukherjee S
BMC Ophthalmol; 2023 Mar; 23(1):121. PubMed ID: 36973703
[TBL] [Abstract][Full Text] [Related]
8. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model.
Moore CP; McHugh JB; Thorne JG; Phillips TE
Invest Ophthalmol Vis Sci; 2001 Mar; 42(3):653-9. PubMed ID: 11222523
[TBL] [Abstract][Full Text] [Related]
9. Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial.
Schechter BA; Urbieta M; Bacharach J; Toyos M; Smyth-Medina R; Mitchell B; Luchs JI
Clin Ophthalmol; 2022; 16():4145-4151. PubMed ID: 36536927
[TBL] [Abstract][Full Text] [Related]
10. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease.
Tauber J; Schechter BA; Bacharach J; Toyos MM; Smyth-Medina R; Weiss SL; Luchs JI
Clin Ophthalmol; 2018; 12():1921-1929. PubMed ID: 30323548
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.
Stevenson D; Tauber J; Reis BL
Ophthalmology; 2000 May; 107(5):967-74. PubMed ID: 10811092
[TBL] [Abstract][Full Text] [Related]
12. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients.
Lee HK; Ryu IH; Seo KY; Hong S; Kim HC; Kim EK
Ophthalmology; 2006 Feb; 113(2):198-205. PubMed ID: 16360211
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A.
Brignole F; Pisella PJ; De Saint Jean M; Goldschild M; Goguel A; Baudouin C
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):90-5. PubMed ID: 11133852
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of HL036 versus Cyclosporine A in the Treatment of Naturally Occurring Canine Keratoconjunctivitis Sicca.
Lee HB; Choi HJ; Cho SM; Kang S; Ahn HK; Song YJ; Kim YJ; Son WC
Curr Eye Res; 2018 Jul; 43(7):889-895. PubMed ID: 29634381
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 1% cyclosporine eye drops in olive oil and in linseed oil to treat experimentally-induced keratoconjunctivitis sicca in rabbits.
Parrilha LR; Nai GA; Giuffrida R; Barbero RC; Padovani LD; Pereira RH; Silva DA; Silva MC; Diniz MS; Andrade SF
Arq Bras Oftalmol; 2015; 78(5):295-9. PubMed ID: 26466228
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops.
Kaswan RL; Salisbury MA; Ward DA
Arch Ophthalmol; 1989 Aug; 107(8):1210-6. PubMed ID: 2757551
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
[TBL] [Abstract][Full Text] [Related]
18. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca.
Berdoulay A; English RV; Nadelstein B
Vet Ophthalmol; 2005; 8(4):225-32. PubMed ID: 16008701
[TBL] [Abstract][Full Text] [Related]
19. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca.
Laibovitz RA; Solch S; Andriano K; O'Connell M; Silverman MH
Cornea; 1993 Jul; 12(4):315-23. PubMed ID: 8339560
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
Pflugfelder SC; Maskin SL; Anderson B; Chodosh J; Holland EJ; De Paiva CS; Bartels SP; Micuda T; Proskin HM; Vogel R
Am J Ophthalmol; 2004 Sep; 138(3):444-57. PubMed ID: 15364229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
